PARIS, France — September 30, 2026
Egle Therapeutics reported positive Phase 1 data for EGL-003, an investigational Treg-selective interleukin-2 (IL-2) agonist, showing favorable safety and selective, dose-dependent expansion of regulatory T cells in healthy volunteers. The findings were presented at the 35th Congress of the European Academy of Dermatology and Venereology (EADV) in Vienna and included safety, pharmacokinetic and pharmacodynamic results from 24 participants across four single ascending dose cohorts. EGL-003 was well tolerated across the evaluated doses, with no serious adverse events reported. The company said the findings support progression into a multiple ascending dose proof-of-concept study in adults with moderate-to-severe atopic dermatitis, planned to begin in the fourth quarter of 2026.
EGL-003 Produces Selective Treg Expansion
EGL-003 produced dose-dependent expansion of total Tregs without corresponding increases in conventional CD4, CD8 or NK cell populations. Across the single ascending dose range of 0.5, 1.5, 2.5 and 5 µg/kg, the treatment induced approximately 8- to 21-fold increases in activated CD25-bright Tregs, with expansion observed for up to 28 days. Egle also reported increased expression of Treg activation and suppressive-function markers including CD25, CTLA-4, FoxP3, ICOS, HLA-DR and Ki67. Plasma concentrations of the anti-inflammatory cytokine IL-10 increased with kinetics that paralleled Treg expansion. The company said these pharmacodynamic findings support sustained biological engagement of Tregs, although the clinical significance of these biomarker changes remains to be established in patients with autoimmune disease
Phase 1 Shows Favorable Safety Profile
The Phase 1 study enrolled 24 healthy volunteers who each received a single subcutaneous dose of EGL-003, with participants assessed for pharmacokinetic and pharmacodynamic effects through Day 8, except for the 2.5 µg/kg cohort, which was followed through Day 56. No serious adverse events were reported across the four dose cohorts. Injection-site reactions were the most common findings and were mild and self-limited, while flu-like symptoms were reported at the two highest doses and were generally mild. Egle also reported an increase in circulating CLA-positive Tregs followed by a decline below baseline, a pattern the company said was consistent with potential migration toward skin tissue. However, the study did not directly demonstrate tissue migration, and the disease-modifying significance of the finding requires further clinical evaluation
Egle Plans Atopic Dermatitis Proof-of-Concept Study
Egle plans to advance EGL-003 into a randomized, double-blind, placebo-controlled multiple ascending dose study in approximately 50 to 100 adults with moderate-to-severe atopic dermatitis. The planned study is expected to begin in Q4 2026, starting with a 1.5 µg/kg dose administered every four weeks, with subsequent cohorts evaluating doses up to 5 µg/kg on four- or two-week schedules based on emerging data. Safety will be the primary endpoint, while secondary assessments will include Eczema Area and Severity Index (EASI) and validated Investigator Global Assessment (vIGA) scores, with exploratory analyses of pharmacodynamic biomarkers in blood and skin. Egle is targeting preliminary efficacy data in Q2 2027 and a full assessment in Q4 2027. EGL-003 remains investigational, and efficacy in atopic dermatitis has yet to be established.
Source :Egle Therapeutic, press release



